We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.48B
AUM Growth
+$175M
Cap. Flow
-$85.7M
Cap. Flow %
-5.8%
Top 10 Hldgs %
38.11%
Holding
211
New
41
Increased
36
Reduced
32
Closed
77

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$10.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.84M
3
HOWL icon
Werewolf Therapeutics
HOWL
+$9.68M
4
ALT icon
Altimmune
ALT
+$9.34M
5
TWLO icon
Twilio
TWLO
+$9.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.7M
2
ABBV icon
AbbVie
ABBV
+$26.3M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.6M
5
PANW icon
Palo Alto Networks
PANW
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Miscellaneous 26%
3 Technology 8.46%
4 Industrials 5.02%
5 Financials 2.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMCR icon
151
Immunocore
IMCR
$1.66B
– –
-36,000
Closed -$1.53M
IMVT icon
152
Immunovant
IMVT
$7.78B
– –
-158,500
Closed -$2.54M
IONS icon
153
Ionis Pharmaceuticals
IONS
$7.77B
– –
-145,476
Closed -$5.7M
JNJ icon
154
CALL
Johnson & Johnson
JNJ
$651B
– –
-200,000
Closed -$32.9M
KALV
155
DELISTED
KalVista Pharmaceuticals
KALV
– –
-258,880
Closed -$6.65M
LRMR icon
156
Larimar Therapeutics
LRMR
$395M
– –
-100,000
Closed -$1.46M
MREO
157
Mereo BioPharma
MREO
$46.3M
– –
-1,312,415
Closed -$4.42M
NVMI
158
Nova
NVMI
$11.1B
– –
-8,556
Closed -$779K
OBIO icon
159
Orchestra BioMed
OBIO
$347M
– –
-100,000
Closed -$1.12M
ORIC icon
160
Oric Pharmaceuticals
ORIC
$1.34B
– –
-169,900
Closed -$4.16M
PANW icon
161
Palo Alto Networks
PANW
$307B
– –
-193,800
Closed -$10.4M
PRGO icon
162
CALL
Perrigo
PRGO
$1.87B
– –
-210,000
Closed -$8.5M
QSI icon
163
CALL
Quantum-Si Incorporated
QSI
$169M
– –
-85,000
Closed -$1.01M
QSI icon
164
Quantum-Si Incorporated
QSI
$169M
– –
-172,396
Closed -$2.06M
TERN
165
DELISTED
Terns Pharmaceuticals
TERN
– –
-70,000
Closed -$1.54M
TIL icon
166
Instil Bio
TIL
$48.9M
– –
-4,750
Closed -$2.38M
TLT icon
167
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$47.1B
– –
-60,000
Closed -$8.13M
VRTX icon
168
Vertex Pharmaceuticals
VRTX
$131B
– –
-5,530
Closed -$1.19M
WGS icon
169
GeneDx Holdings
WGS
$3.13B
– –
-606
Closed -$298K
ZNTL icon
170
Zentalis Pharmaceuticals
ZNTL
$292M
– –
-175,140
Closed -$7.6M
PVLA
171
Palvella Therapeutics
PVLA
$2.22B
– –
-8,125
Closed -$1.67M
GRTX
172
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
– –
-323,348
Closed -$2.85M
ALPN
173
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-198,260
Closed -$2.1M
NBSE
174
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-1,595
Closed -$236K
GMDA
175
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-178,450
Closed -$1.44M
5 6
7
8 9

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sphera Funds Management held 211 positions worth $1.48B, up 13% from $1.3B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management withdrew a net $85.7M in Q2 2021, closing 77 positions and reducing 32 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 63% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Sphera Funds Management opened a new position in Iovance Biotherapeutics worth $9.85M.

  • Sphera Funds Management's largest Q2 2021 buy was Iovance Biotherapeutics: 378,642 shares worth $9.85M.
  • Sphera Funds Management added most to AstraZeneca in Q2 2021, an estimated $10.3M increase.
  • Sphera Funds Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $49.7M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $12.6M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $1.48B portfolio in Q2 2021.
  • Sphera Funds Management opened 41 new positions and closed 77 in Q2 2021.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $1.48B.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.